EP
TARA icon

Essential Partners’s Protara Therapeutics TARA Stock Holding History

Essential Partners’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37.4K Sell
9,802
-70
-0.7% -$333 0.02% 689
2026
Q1 		$51.4K Buy
9,872
+77
+0.8% +$456 0.02% 594
2025
Q4 		$52.2K Buy
9,795
+3,847
+65% +$21.4K 0.02% 597
2025
Q3 		$25.9K Buy
+5,948
New +$19.3K 0.01% 807

Other funds holding TARA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

Essential Partners's TARA Position: Q2 2026 in Review

Essential Partners reduced its Protara Therapeutics (TARA) stake by 0.71% in Q2 2026, selling an estimated $333 and leaving 9,802 shares worth $37.4K. The position accounts for 0.02% of the portfolio, ranked #689.

Essential Partners first reported a position in TARA in Q3 2025 and has held it in 4 quarters since. The position peaked at $52.2K in Q4 2025. 120 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

  • Essential Partners held 9,802 shares of Protara Therapeutics worth $37.4K as of Q2 2026.
  • Essential Partners sold 70 Protara Therapeutics shares in Q2 2026, an estimated $333.
  • Protara Therapeutics made up 0.02% of Essential Partners's portfolio in Q2 2026, its #689 holding.
  • Essential Partners first reported a position in Protara Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Essential Partners's Protara Therapeutics position peaked at $52.2K in Q4 2025.
  • 120 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.